Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plinabulin + Docetaxel in Advanced NSCLC
NCT00630110Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2008
- Primary completion
- Jun 2011
- Countries
- 6
- Sponsor
- Nereus Pharmaceuticals
- Modality
- Small Molecules
- Drugs
- plinabulin
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, randomised, open-label trial of plinabulin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Nereus Pharmaceuticals. Primary endpoint: Overall Survival. Started Feb 2008; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Docetaxel
Docetaxel (75 mg/m2)
Plinabulin + Docetaxel
Plinabulin (30 mg/m2) + Docetaxel (75 mg/m2)
03
Endpoints
Primary
Overall Survival
Secondary
Response Rate
Duration of Response
6-month Survival Rate
Progression-Free Survival
Safety and Adverse Events
Pharmacokinetics
Beyond the preview
Go deeper on NCT00630110.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00630110.